The invasion of intraductal papillary-mucinous neoplasm (IPMN) is sometimes difficult to diagnose using only ordinary hematoxylin-eosin sections. The aim of this study was to evaluate the invasion of IPMN more precisely using thrombospondin-1 (TSP1) immunohistochemistry as a useful adjunct to morphological examination. Eighty patients that underwent primary resection for pancreatic IPMNs were retrospectively analyzed. The 80 IPMNs were studied for the expression of TSP1, MUC1-CORE, MUC2, and MUC5AC. The cases were evaluated for dysplasia, the presence of invasion, hisological subtypes, and survival. The 80 IPMNs were classified into 29 intraductal papillary-mucinous adenomas (IPMAs), 10 borderline IPMNs, 18 noninvasive intraductal papillary-mucinous carcinomas (IPMCs), and 23 invasive IPMCs according to the WHO classification. Invasive IPMCs were further divided into 12 minimally invasive IPMCs (MI-IPMCs) and 11 invasive carcinomas originating from IPMCs (IC-IPMCs) according to the Japan Pancreatic Society classification. The rate of strongly positive cases with more than 30% of the cancer stroma area expressing TSP1 was significantly higher in MI-IPMC and IC-IPMC than in noninvasive IPMC (P = 0.035, 0.005). Furthermore, patients in the strongly positive group had a significantly poorer prognosis compared to patients in the negative-weakly positive group (P = 0.008, log-rank test). Of the 80 tumors, 22 were classified into gastric-, 45 into intestinal-, 7 into pancreatobiliary-, and 6 into oncocytic-type IPMNs according to criteria described previously. The cases with a strongly positive expression of TSP1 were frequently detected in the pancreatobiliary and oncocytic types (P = 0.001). In conclusion, stromal TSP1 expression is a prognostic indicator and a new marker of invasiveness in IPMN.
Intraductal papillary-mucinous neoplasms of the pancreas (IPMNs) are a well-characterized group of intraductal, mucin-producing, cystic neoplasms of the pancreas with a clear malignant potential (1, 2) . A half of surgically resected IPMNs are intraductal papillary-mucinous adenoma (IPMA) or borderline IPMN even under current international criteria (21) , and it is still unclear when they change to noninvasive intraductal papillary-mucinous carcinoma (IPMC), how long IPMC retains a status of "carcinoma in situ", and when IPMC achieves invasiveness. Particularly, invasive carcinoma originating from intraductal papillary-mucinous carcinoma (IC-IPMC) showed similar malignant behavior compared with conventional invasive ductal carcinoma both clinically and histologically (15) . Minimally invasive IPMC (MI-IPMC) has been categorized within the classification of pancreatic carcinoma used by pancreatic IPMNs at Tokai University Hospital, Japan. All cases were indicated for resection under the International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasm and Mucinous Cystic Neoplasm of the Pancreas (21) . There were no operation-related deaths, and all patients underwent macroscopically curative resection without any residual tumor. Cases which also showed invasive carcinoma of the pancreas and were not directly associated with IPMNs were excluded. The patients comprised 56 males and 24 females, with a median age of 67 (40 to 81) years. Every patient was followed-up in the outpatient clinic every 1 to 3 months during the first postoperative year, and every 6 to 12 months thereafter. Clinical data and follow-up information for every patient were obtained from the medical records. The median follow-up period after surgery was 28.5 (3.3 to 121.4) months.
Pathologic examination. The pancreatic tissue specimens for histological analysis were rapidly fixed in 10% buffered formalin for 24 to 48 h, routinely embedded in paraffin, and cut into serial 5-μm-thick slices, horizontally to sagittally across the main duct in the pancreas head, and sagittally in the pancreas body and tail. After the histopathologic examination of all sections, lesions were classified as IPMA, borderline IPMN, or IPMC according to the WHO classification (23) . Invasive IPMC is classified into 2 categories: MI-IPMC and IC-IPMC. An infiltrative distance of 5 mm or less was regarded as minimal invasion in our study.
Immunohistochemical analysis. As primary antibodies, the following mouse monoclonal antibodies were used: a monoclonal antibody to MUC1-core (clone Ma552; Novocastra Laboratories, Ltd., Newcastle upon Tyne, UK; 1 : 100), a monoclonal antibody to MUC2 (clone Ccp58; Novocastra Laboratories, Ltd.; 1 : 100), a monoclonal antibody to MUC5AC (clone CLH2; Novocastra Laboratories, Ltd.; 1 : 100), and a monoclonal antibody to TSP1 (clone 8A6b; Novocastra Laboratories, Ltd.; 1 : 100). For TSP1, sections (5 μm) cut from paraffinembedded tissues were deparaffinized, and endogenous peroxidase activity was quenched by incubation in 0.3% H 2 O 2 in methanol for 30 min. Sections were placed in a jar with citrate buffer solution, and microwaved for 10 min for antigen retrieval (10) . Nonspecific binding was blocked with normal sheep serum (Cosmo Bio Co., Ltd., Tokyo, Japan) in phosphate-buffered saline (PBS), and then slides were the Japan Pancreatic Society (JPS) since 1993 (23) . In the JPS classification, invasive IPMC is classified into 2 categories: MI-IPMC and IC-IPMC, with the latter being more advanced. A few reports have indicated that MI-IPMC shows a better surgical outcome than IC-IPMC (14, 19) . However, the definition of "minimally invasive" has not been made clear, and diagnosis is often difficult using only ordinary hematoxylin-eosin sections. There is therefore a potential for misdiagnosing IPMC or IC-IPMC as MI-IPMC. Recently, other researchers have reported laminin-5-γ-2 or periostin as a useful marker for detecting invasive tumor cells in IPMNs, which might be associated with cancer-cell invasiveness (7, 8) . Pericellular proteolysis is crucial in tumor cell invasion. The plasminogen/plasmin system is one of the main protease systems involved in cancer progression. Thrombospondin-1 (TSP1) can bind to several proteases, including urokinase plasminogen activator, thrombin, plasmin, cathepsin G, and neutrophil elastase. Several investigators demonstrated that TSP1 may play an important role in tumor cell adhesion and invasion by regulating the plasminogen/plasmin system (3, 4, 6, 16, 18) . Previously, we reported that TSP1 plays important roles in cancer cell growth and the metastasis of human pancreatic cancer, and that stromal TSP1 immnoreactivity is a good prognostic indicator for patients with pancreatic cancer (22) . In the present study, we examined stromal TSP1 expression as a prognostic indicator and a new marker of stromal invasiveness in IPMN. Based on the results on an immunohistochemical study of TSP1, we investigated the therapeutic strategy according to the histological subtype of IPMN. Recently, there have been some reports on the relationship between the histological subtype and invasiveness in IPMN (5, 12, 13, 17, 20, 25) . We also analyzed the correlation between the subtype and stromal TSP1 expression in IPMNs to clarify which subtypes tended to achieve invasiveness fast and which tended to retain the status of adenoma in the pancreatic duct, and discussed the clinicopathological significance.
MATERIALS AND METHODS
Patient characteristics and surgical specimens. All tissue specimens were obtained through the surgical resection of IPMNs. We reviewed data retrospectively with additional independent histopathologic confirmation. Between April 1991 and December 2008, 80 patients underwent primary resection for body at 1 : 100 (Amersham International Plc., Buckinghamshire, UK), were applied for 60 min at room temperature. The sections were then treated with streptavidin-conjugated horseradish peroxidase for 30 min at room temperature. The reaction products were visualized using the action of DAB for 4 min in Tris buffer. Counterstaining was performed using hematoxylin. The histologic tumor subtype was classified according to the consensus criteria of Furukawa et al. (9) .
Expression patterns of TSP1. Immunohistochemical expression patterns of TSP1 were divided into two groups as follows: a) strongly positive group, TSP1-diffusely positive cases with more than 30% of the cancer stroma positive for TSP1 (Fig. 1) ; b) negative-weakly positive group, TSP1-focally positive cases with less than 30% of the cancer stroma positive for TSP1, including TSP1-negative cases with greater than 90% of the cancer stroma negative for TSP1.
Statistical analysis. Descriptive statistics were employed to examine the demographic characteristics of the study population. Data are expressed as mediincubated with mouse anti-human TSP1 monoclonal antibody overnight at 4°C. Immunoreactivity was detected employing the peroxidase-labeled streptavidin biotin (LSAB) method (Dako A/S). Slides were subsequently incubated with biotinylated anti-mouse Ig(Fab) 2 antibody at 1 : 100 for 60 min, and immunoreactivity was detected using horseradish peroxidase-conjugated streptavidin for 30 min. The reaction products were visualized using the action of diaminobenzidine tetrahydrochloride (DAB) for 4 min in Tris buffer. Counterstaining was performed using hematoxylin.
To detect mucin glycoproteins, the sections were pretreated with autoclave heating (ES-215; Highpressure steam sterilizer; TOMY, Japan) at 121°C for 4 min for antigen retrieval. Nonspecific binding was abolished with diluted normal sheep serum (Cosmo Bio Co., Ltd.). Next, the sections were overlayed with primary monoclonal antibodies at 1 : 100 optimally diluted with 1% bovine serum albumin containing PBS and left overnight at 4°C in a moist chamber. Immunoreactivity was detected by the LSAB method (Dako A/S) with modifications. After being washed with PBS, the secondary antibodies, biotinylated anti-mouse Ig(Fab) 2 anti- 
Association between stromal TSP1 expression and the malignant status of IPMN
To evaluate the stromal invasiveness of IPMNs, we examined the stromal TSP1 expression in IPMNs. Diffuse positivity with more than 30% of the cancer stroma positive for TSP1 was identified in one of twenty-nine IPMA cases (3.4%), zero of ten borderline IPMN cases (0%), five of eighteen IPMC cases (27.8%), eight of twelve MI-IPMC cases (66.7%), and nine of eleven IC-IPMC cases (81.8%) (Table 1). The rate of stromal TSP1 expression was significantly higher in MI-IPMC and IC-IPMC than in noninvasive IPMC (P = 0.035, 0.005, Table 1 ), but there was no significant difference between MI-IPMC and IC-IPMC. Three cases (25.0%) of MI-IPMC and seven cases (63.6%) of IC-IPMC were diffusely positive, with more than 50% of the cancer stroma positive for TSP1, a similar level compared with conventional invasive ductal carcinoma of the pancreas (data not shown) (22) . Furthermore, patients in the strongly positive group with more than 30% of the cancer stroma positive for TSP1 showed a significantly poorer prognosis compared to that of patients in the negative-weakly positive group (P = 0.008, log-rank test, Fig. 2 ).
Comparison of subtypes and clinicopathological features
To compare the histologic subtype and malignant diagnosis in IPMN, we classified all cases according to the consensus criteria for the classification of IPMN subtypes based on the morphological features and immunohistochemical reactivity to MUC1-CORE, MUC2, and MUC5AC, according to criteria described previously (9) . Of the 80 tumors, 22 (27.5%) were classified into the gastric type (12 IPMA, ans (25th and 75th percentiles). Statistical comparisons between two groups were made using the Chi-square test. A P-value < 0.05 was considered to indicate significance. Survival times were measured from the date of surgery, and death from all causes (without differentiating between deaths resulting from IPMN or other causes) was taken as the outcome. Survival curves were traced using the Kaplan-Meier method, and a comparison of survival curves was carried out employing the log-rank test. All analyses were performed using the statistical software package SPSS II (version 11.0; SPSS, Tokyo, Japan).
RESULTS

Clinicopathological features
The operative procedures included 3 pancreatoduodenectomies (PDs), 41 pylorus-preserving PDs, 1 subtotal stomach-preserving PD, 17 distal pancreatectomies, 11 median pancreatectomies, 4 total pancreatectomies, 2 partial resections of the pancreas head, and 1 duodenal-preserving pancreas head resection. Eighty IPMNs were classified into 29 IPMAs, 10 borderline IPMNs, 18 noninvasive IPMCs, and 23 invasive IPMCs according to the WHO classification. None showed an ovarian-like stroma, and all lesions communicated with the pancreatic ductal system. Invasive IPMCs were further divided into 12 MI-IPMCs and 11 IC-IPMC according to the JPS classification. The macroscopic (main duct type, including the mixed type or branch duct type) types of IPMNs were determined by clinical imaging studies and investigation of the resected tumors, according to criteria described previously (21) , as follows: main duct type, 31 tumors; branch duct type, 49 tumors. The macroscopic types were found to be significantly associated with the histological diagnosis: 21 (67.7%) of 31 tumors of the main duct type Table 2) . Fifty-seven patients were negative-weakly positive for TSP1, and their subtypes were 21 gastric-, 32 intestinal-, 2 pancreatobiliary-, and 2 oncocytic-type IPMNs. Twenty-three patients were strongly positive for TSP1, and their subtypes were 1 gastric-, 13 intestinal-, 5 pancreatobiliary-, and 4 oncocytic-type IPMNs (P = 0.001, Table 2 ).
The preoperative diagnoses of the macroscopic type were 31 main duct-and 49 branch duct-type IPMNs. There was no significance in the relationship between the macroscopic type and subtype of IPMN (P = 0.581, Table 2 ). Fig. 2 Patients in the strongly positive group, with more than 30% of the cancer stroma positive for TSP1 (---, n = 23), showed a significantly poorer prognosis compared to that of patients in the negative-weakly positive group (-, n = 57; P = 0.008 log-rank test). (9, 13, 17) . However, cases of gastric-type IPMNs tended to show a higher incidence of branch duct-type IPMNs, but there was no significant association between the histological subtype and macroscopic type in our study. Therefore, it might be difficult to diagnose each subtype of IPMN preoperatively based solely on an imaging study. Recently, however, several investigations on pancreatic juice cytology in IPMN revealed that it can be subclassified not only histomorphologically but also based on cytological findings (11, 24) . Combining routine cytological findings with the subclassification of IPMNs by MUC immunocytochemistry will be useful for preoperative evaluation of the malignant potential of IPMNs.
Because most IPMNs are slow-growing, affect elderly people, and the prognosis may be favorable even when IPMN is malignant, the benefits of surgical treatment must be balanced against the operative and postoperative risks. Our study revealed that gastric-type IPMNs could be followed up under observation during a longer period, and that pancreatobiliary and oncocytic types should be resected earlier than previously thought.
In conclusion, we have shown that stromal TSP1 expression is a prognostic indicator and a new marker of invasiveness in IPMN. Also, we can evaluate invasiveness in IPMN more precisely using TSP1 immunohistochemistry as a useful adjunct to morphological examination.
REFERENCES DISCUSSION
The number of surgically resected cases of IPMN has recently increased because of advances in imaging diagnosis and operative procedures. A therapeutic strategy has not been established for IPMN. If possible, surgeons should resect IPMNs only with a status of "carcinoma in situ" before achieving the status of invasive IPMC, but half of resected IPMNs revealed IPMA or borderline IPMN. Furthermore, we should also pay attention to how long IPMCs retain the status of "in situ", and how fast they become stromally invasive, because IC-IPMC showed similar malignant behavior compared with conventional invasive ductal carcinoma both clinically and pathologically. Therefore, pathologists were responsible for the diagnosis of invasiveness in IPMN. The diagnosis of minimally invasive IPMC in IPMN is sometimes difficult because of a decreased stromal volume due to the compression of cystic lesions, and insufficient knowledge on the primary invasion of IPMC. In this study, we reviewed 80 surgically resected cases of IPMN to evaluate invasiveness by the immunohistochemical study of TSP1. The rate of strongly positive cases, with more than 30% of the cancer stroma positive for TSP1, was significantly higher in MI-IPMC and IC-IPMC than in IPMC, and strongly positive expression was frequently detected increasingly from noninvasive IPMC to MI-IPMC, and IC-IPMC. Patients in the strongly positive group had a significantly poorer prognosis compared to that of patients in the negative-weakly positive group. To our knowledge, this is the first report describing the relationship between invasiveness and TSP1 immunoreactivity in IPMN of the pancreas. Several investigators have reported clinicopathological and biological differences on comparing histologic subtypes of IPMN (5, 12, 13, 17, 20, 25) . Using the TSP1 expression pattern, we also analyzed differences in stromal invasion within histological subtypes of IPMN. Even if tumors are indicated for resection under the International Consensus Guidelines for Management of IPMN, most gastric-type IPMNs retain the status of IPMA or borderline IPMN at the time of resection. However, half of the specimens in resected intestinal-type IPMNs showed IPMC, and 20% showed invasiveness. Stromal invasiveness and stromal TSP1 expression were more frequently detected in the pancreatobiliary and oncocytic types at the time of resection; in other words, the status of "carcinoma in situ" might be retained for only a short period in
